Small molecule · Inhibitor of menin (MEN1) · developed by Kura
Ziftomenib is a small-molecule menin inhibitor that blocks the interaction between menin and KMT2A. In NPM1-mutant leukemia, this disruption reduces the oncogenic activity of mutant NPM1 and promotes differentiation of leukemic cells. It is studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 9, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07007312 | Phase 3 | Acute Myeloid Leukemia (AML) | Recruiting | KURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia (AML)
Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.
See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KURA catalysts and pipeline →